We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A district court threw out Mylan’s attempt to gain 180-day exclusivity for generic versions of Novartis’ high blood pressure drug Diovan, saying the FDA properly granted the marketing perks to Ranbaxy.